A practical reference on lyophilization: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-28 and is reviewed periodically as new material appears.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
Lyophilized tesamorelin is generally stored refrigerated at temperatures between 2 and 8 degrees Celsius. The solid form is comparatively stable when kept dry and protected from light. Moisture uptake can promote aggregation and degradation, so sealed containers with desiccant are common. Researchers typically avoid repeated temperature cycling, which may stress the peptide. Documentation accompanying reference materials usually specifies a shelf life under these conditions.
Once reconstituted, the peptide is handled as a solution and is less stable than the lyophilized powder. Aqueous solutions are commonly kept cold and used within a defined period. Buffer composition and pH influence degradation rates, with extremes of acidity or alkalinity accelerating hydrolysis. Preservatives may be added in multi-dose formats to limit microbial growth. Freezing and thawing of solutions is generally avoided because it can cause precipitation or loss of activity.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
The peptide is supplied as a lyophilized powder in single-use vials and is normally kept refrigerated between two and eight degrees Celsius, protected from light. Once dissolved, the solution is handled carefully because peptide bonds and the acyl modification can degrade under warm or alkaline conditions. Vials are inspected for cracks, and the powder is checked for color and uniformity before handling. Temperature excursions during shipping are a frequent reason for quality questions.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from truncated or oxidized forms. Mass spectrometry confirms the expected molecular weight, and peptide mapping after enzymatic digestion verifies the amino acid sequence. Water content is measured because residual moisture affects stability, and tests for aggregates or particulates are standard for injectable peptides. Circular dichroism can indicate whether the molecule has adopted an unexpected secondary structure in solution.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
Regulatory position depends on jurisdiction and on the form in which the material is sold. A branded product holds approval in the United States for a defined indication, and prescribing is confined to that label. Material marketed for laboratory research is not evaluated for human use and carries no such clearance. Independent verification therefore rests on certificates of analysis, third-party testing, and documented chain of custody. The substance also appears on the World Anti-Doping Agency prohibited list within the category covering growth hormone-releasing factors.
Lyophilized material is typically held under refrigeration between two and eight degrees Celsius, shielded from light and ambient moisture. Peptides of this size adsorb to glass and plastic, so working procedures often call for low-binding containers and as few transfers as possible. Absorbed water during weighing shifts the apparent mass of a sample, and controlling room humidity reduces that source of error. Once dissolved, solutions are kept cold and used within the interval printed on the accompanying label or certificate. Degradation accelerates markedly in dilute aqueous form.
Identity and purity are judged through a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact peptide from truncated, oxidized, and deamidated variants, and the resulting peak-area percentages yield a purity figure. Electrospray ionization mass spectrometry confirms the expected molecular mass and can expose unanticipated modifications. Amino acid analysis and peptide mapping support sequence fidelity, while water content, pH, sterility, and bacterial endotoxin testing describe the physical and microbiological attributes of a finished lot.
In 1493, Diego Álvarez Chanca accompanied Christopher Columbus on his second voyage to the West Indies. Upon returning to Spain with chili peppers, Chanca became the first European to document their medicinal uses in the Old World, publishing his observations in 1494. Columbus and his crew called the Capsicum fruits "peppers" (pimientos in Spanish) because they were pungent like black pepper (Piper nigrum). The introduction of chilies to Europe formed part of the wider interchange of plants, animals, and cultures between the New World and the Old World known as the Columbian exchange. Unlike Piper vines, which grow naturally only in the tropics, chilies could be grown in temperate climates. By the mid-1500s, they had become a common garden plant in Spain and were incorporated into numerous dishes. By 1526, they had appeared in Italy, in 1543 in Germany, and by 1569 in the Balkans, where they came to be processed into paprika.
==== Refeeding syndrome ==== When a malnourished person is refed too quickly, they may develop refeeding syndrome (RFS), which can be life-threatening. Factors associated with increased risk for RFS include:
1955: the Mexican League, previously independent, was classified as Double-A 1961: final season of the Southern Association 1963: the Eastern League and original South Atlantic League were moved from Class A to Double-A 1964: the original South Atlantic League was reconstituted as the Southern League 1967: the Mexican League moved to Triple-A Entering the 2020 minor league season (which was not played, due to the COVID-19 pandemic) the Texas League had been in Double-A since 1946, the Eastern League since 1963, and the Southern League since 1964. Prior to the 2021 season, Major League Baseball (MLB) reorganized the minor leagues. At that time, the existing leagues were temporarily renamed: Eastern League as Double-A Northeast, Southern League as Double-A South, and Texas League as Double-A Central. Following MLB's acquisition of the rights to the names of the historical minor leagues, MLB announced on March 16, 2022, that the leagues would revert to their prior names, effective with the 2022 season.
== Glycogen synthase == Glycogen synthase is an enzyme that is responsible in glycogen synthesis. It is activated by glucose 6-phosphate (G6P), and inhibited by glycogen synthase kinases (GSK3). Those two mechanisms play an important role in glycogen metabolism.
Within months of the collapse of the Third Coalition, the Fourth Coalition (1806–1807) against France was formed by Britain, Prussia, Russia, Saxony, and Sweden. In July 1806, Napoleon formed the Confederation of the Rhine out of the many small German states which constituted the Rhineland and most other western parts of Germany. He amalgamated many of the smaller states into larger electorates, duchies, and kingdoms to make the governance of non-Prussian Germany smoother. Napoleon elevated the rulers of the two largest Confederation states, Saxony and Bavaria, to the status of kings. In August 1806, the Prussian king, Frederick William III, decided to go to war independently of any other great power. The army of Russia, a Prussian ally, in particular, was too far away to assist. On 8 October 1806, Napoleon unleashed all the French forces east of the Rhine into Prussia. Napoleon defeated a Prussian army at Jena (14 October 1806), and Davout defeated another at Auerstädt on the same day. 160,000 French soldiers (increasing in number as the campaign went on) attacked Prussia, moving with such speed that they destroyed the entire Prussian Army as an effective military force. Out of 250,000 troops, the Prussians sustained 25,000 casualties, lost a further 150,000 as prisoners, 4,000 artillery pieces, and over 100,000 muskets. At Jena, Napoleon had fought only a detachment of the Prussian force. The battle at Auerstädt involved a single French corps defeating the bulk of the Prussian army. Napoleon entered Berlin on 27 October 1806.
Sources: en.wikipedia.org
=== MicroRNAs === MicroRNAs are a factor in the development of that type of disease. MicroRNAs usually operate as a negative regulator of the expression of target proteins, and their increased concentration after biologic treatment (bDMARDs) or after anti-rheumatic drugs. The levels of miRNA before and after anti-TNFa/DMRADs combination therapy are potential novel biomarkers for predicting and monitoring the outcome. For instance, some of them were found significantly upregulated by anti-TNFa/DMRADs combination therapy. For example, miRNA-16-5p, miRNA-23-3p, miRNA125b-5p, miRNA-126-3p, miRNA-146a-5p, miRNA-223-3p. Curious fact is that only responder patients showed an increase in those miRNAs after therapy, and paralleled the reduction of TNFα, interleukin (IL)-6, IL-17, rheumatoid factor (RF), and C-reactive protein (CRP).
Before analyzing with mass spectrometry, a protein must be accurately isolated and digested. If not isolated, the results will represent a mixture of two or more proteins and will therefore be unreliable in protein identification. Because of this sensitivity, sample preparation is likely the most important step in forming a peptide-mass fingerprint. Isolation of a specific protein is most often done through a form of gel electrophoresis, in which proteins are separated by size and can be subsequently extracted for further preparation. However, they can also be isolated by liquid chromatography. This method also separates proteins by size. Once an individual protein is isolated, it needs to be digested and fractionated for further analysis by a spectrometer. This is done by the addition of proteolytic enzymes such as trypsin and chymotrypsin. Another method commonly used that combines both the isolation and digestion steps is SDS-PAGE, a form of electrophoresis that separates and fractionates proteins simultaneously.
=== Other === In 1964, the company bought the NMR division of the Swiss Trüb-Täuber. Bruker made several offers to take over its supplier Oxford Instruments during the 1970s, but after almost a decade of negotiations, an acquisition was eventually rejected by Oxford Instruments. In 1997, the analytical X-ray division of Siemens was acquired by Bruker. In 2010, Bruker bought 3 product lines from Agilent, which Agilent had acquired from Varian. These included mass spectrometry and gas chromatography instruments. They have since divested these products to Scion Instruments with the exception of the triple quadrupole In 2012, Bruker bought parts of Carestream Health, including their in-vivo imaging portfolio and related aspects. In 2019, Bruker bought Alicona, known for production of metrology equipment based on focus variation, to extend its analytics business in the industrial market. In 2020, Bruker acquired Canopy Biosciences. This acquisition allowed Canopy to leverage Bruker's global infrastructure and expertise in product design and engineering. The financial terms of the deal were not disclosed. In November 2022, it was announced Bruker had acquired the Mountain View-headquartered miniaturized microscope / miniscope company, Inscopix, Inc.
30 August – Nicky Gavron, 82, British politician, deputy mayor of London (2000–2003, 2004–2008). 3 September – Flora Fraser, 21st Lady Saltoun, 93, Scottish peer, member of the House of Lords (1979–2014). 18 September – Malcolm Mitchell-Thomson, 3rd Baron Selsdon, 86, British peer, banker and businessman, member of the House of Lords (1963–2021). 1 October – Michael Ancram, 13th Marquess of Lothian, 79, British politician and peer, three-times MP, member of the House of Lords (since 2010). 2 October – Herman Ouseley, Baron Ouseley, 79, Guyanese-born British civil rights activist and politician, member of the House of Lords (2001–2019). 4 October – Alexander Leitch, Baron Leitch, 76, British businessman and life peer, member of the House of Lords (since 2004). 7 October – Hugh Cholmondeley, 5th Baron Delamere, 90, British peer, member of the House of Lords (1979–1999). 12 October – Alex Salmond, 69, Scottish politician, first minister (2007–2014). 20 October – Paul White, Baron Hanningfield, 84, British politician and life peer, member of the House of Lords (since 1998). 4 November – Robin Renwick, Baron Renwick of Clifton, 86, British diplomat and life peer, ambassador to the United States (1991–1995). 6 November – Anna Lo, 74, Northern Irish politician, MLA (2007–2016). Sir John Nott, 92, British politician, MP (1966–1983) and defence secretary (1981–1983). 20 November – John Prescott, Baron Prescott, 86, British politician, deputy prime minister (1997–2007), first secretary of state (2001–2007), and MP (1970–2010).
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
Refrigeration between 2 and 8 degrees Celsius is typical, with protection from moisture and light. Dry, sealed containers help maintain stability over the labeled shelf life. Temperature cycling is usually minimized.